Nicox SA, an international ophthalmology company, announced that new nonclinical data on NCX 470 demonstrating greater intraocular pressure lowering than Lumigan® upon both single and repeated dosing in an in vivo nonclinical model has been published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.
